USANA Health Sciences came into this print already under pressure, with the stock down sharply over the past quarter. The Q2 earnings shock then hit like a second punch. Shares slid a further 34.2% to US$14.99 after the company reported a loss per share of US$1.16 on revenue of US$223.3m and took a US$29m noncash goodwill impairment tied to Hiya.

For a company long viewed as a steady cash generator in health and wellness, this quarter raised fresh questions about profit quality and the pace of its multi brand expansion. The rest of the earnings detail explains why the reaction has been so extreme.

Concerned that USANA Health Sciences just went from steady earner to an earnings shock story in one quarter? If you prefer companies with stronger balance sheets and more resilient fundamentals, check out our list of list of solid balance sheet and fundamentals stocks (50 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$223.3m vs. US$235.8m (revenue declined 5.3%)
• Net Income, Q2 2026 vs. Q2 2025: loss of US$21.4m vs. profit of US$9.7m (swung further into loss)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$1.16 per share vs. earnings of US$0.52 per share (earnings fell by about US$1.68 per share)
• Trailing 12 Month Net Income, Q2 2026 vs. Q2 2025: loss of US$22.2m vs. profit of US$34.1m (moved from profit to loss over the year)

Prefer clear visuals instead of another wall of earnings tables and impairment footnotes for USANA Health Sciences? Get an at a glance view of the company’s valuation in a simple dashboard through our company report for USANA Health Sciences.

USANA bullish story leans on core strength and cash

For anyone looking at USANA Health Sciences with a cautiously positive lens, the latest numbers point to the core Nutritional business and the balance sheet as the main anchors. Revenue in Q2 2026 of US$223.3m and around US$20m in free cash flow sit alongside about US$169m of cash and no debt. Management kept the core outlook largely intact despite cutting guidance at the venture brands. That supports the idea of a still functioning global wellness platform with financial room to invest through product cycles.

Bearish risks surface in earnings shock and impairments

The bear case around USANA Health Sciences finds support in the swing from a profit of US$9.7m in Q2 2025 to a loss of US$21.4m, and in the trailing 12 month move from a profit of US$34.1m to a loss of US$22.2m. The US$29m goodwill impairment at Hiya, weaker guidance tied to Hiya and Rise Wellness, and a higher effective tax rate all point to pressure on newer growth bets. A 34.2% share price drop after the release shows how quickly confidence can shift when earnings quality is questioned.

Compare USANA Health Sciences' internal story of cash strength and a still intact core business with how analysts are reacting to a share price that just fell 34.2% in a single session. See the consensus price target analysis for USANA Health Sciences to check whether the street views this as a reset opportunity or a sign that expectations are being cut.

Stay Ahead Of Your Next Move

If the Q2 2026 earnings shock at USANA Health Sciences has your attention, register for free with Simply Wall St and add the stock to your Watchlist so you can track price moves against fair value and watch for a potential entry point that fits your plan. Once you decide to take a position, manage it through the Portfolio Command Center, which focuses your view on key events, valuation updates and fundamental shifts instead of day to day noise. For longer term conviction, tap into the Community to see how other investors are interpreting the same data and where the debate is heading. By spotting potential catalysts or emerging risks early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond USANA Health Sciences?

New ideas can move quickly once momentum builds. Spot stocks that might be preparing for a breakout while they are still under the radar for now, act now.

• Jump on potential trend leaders with curated 56 AI infrastructure stocks that could benefit as spending shifts toward the backbone of artificial intelligence.
• Scan for steady income candidates using a hand picked pool of 8 dividend fortresses that focus on durability as well as yield.
• Hunt for potential mispriced opportunities across a refined group of 17 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.